Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.

•This study reports on a pre-specified secondary analysis of the randomized open-label phase II Valentino trial.•Quality of Life (QoL) changes are reported through patient-reported outcomes.•Patients affected by RAS wild type metastatic colorectal cancer were treated in first-line with panitumumab (pan) plus/minus fluorouracil/leucovorin maintenance after FOLFOX-pan induction.•The results of this study showed an early deterioration of QoL during induction with partial recovery during maintenance.•No significant QoL differences between the two maintenance treatment arms are reported.